Dr
Haider
Al-Janabi
BSc, MSc, PhD
School of Medicine and Population Health
Senior Postdoctoral Research Associate
+44 114 215 9209
Full contact details
The Medical School
- Profile
-
Dr Haider Al-Janabi is a Senior Postdoctoral Research Associate in the Division of Clinical Medicine at the University of Sheffield.
His research focuses on tumour immunology and the tumour microenvironment, particularly macrophage–tumour interactions, bone marrow niche biology, cancer dormancy and treatment resistance. His current research investigates how macrophages contribute to multiple myeloma dormancy and resistance to treatment, and explores therapeutic strategies to target these interactions.
He has experience in preclinical cancer models, macrophage biology, targeted drug delivery, oncolytic virotherapy and translational cancer research.
In 2026, he was awarded funding from the Catalyst for Cancer Fund to support research into macrophage-related mechanisms of myeloma dormancy and treatment resistance.
- Qualifications
-
PhD in Immuno-Oncology, University of Sheffield (2019)
MSc in Immunology, Al-Nahrain University, Baghdad (2013)
BSc in Biotechnology, Al-Technology University, Baghdad (2008)
- Research interests
-
Tumour immunology
Tumour microenvironment
Macrophage biology and tumour-associated macrophages
Mone marrow niche biology
Multiple myeloma
Cancer dormancy and drug resistance
Macrophage-targeted therapies
Cancer immunotherapy
Targeted drug delivery and oncolytic virotherapy
- Publications
-
Journal articles
- Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7). View this article in WRRO
- Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus. Small, 18(13). View this article in WRRO
- Macrophage Regulation of the Development of Castration-Resistant Prostate Cancer. Cancer Research, 81(21), 5399-5400.
- Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.. Mol Cancer Ther.
- Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells. International Journal of Pharmaceutics, 555, 322-336. View this article in WRRO
Conference proceedings
- Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Cancer Research, Vol. 79(13_Supplement)
- Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Cancer Research, Vol. 79(13_Supplement)
Other
- Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7). View this article in WRRO
- Grants
-
Catalyst for Cancer Fund – Round 1 (2026) — Awarded. £10,000 to support research into macrophage-related mechanisms of multiple myeloma dormancy and treatment resistance.
- Teaching interests
-
Cancer biology, tumour immunology, tumour microenvironment, macrophage biology and cancer immunotherapy.
- Teaching activities
-
Contributes to teaching on the Cancer Biology and Tumour Microenvironment module at the University of Sheffield.
- Professional activities and memberships
-
Awarded the Catalyst for Cancer Fund in 2026 to support research into macrophage-related mechanisms of myeloma dormancy and treatment resistance.
Involved in research collaboration and grant development in cancer research, with a focus on tumour immunology, macrophage-mediated treatment resistance and translational research.